What was announced
The FDA issued a discussion paper seeking input on risk assessment, premarket evaluation and postmarket monitoring for generative-AI-enabled medical devices.
Why it matters to an independent practice
Even before rules are finalized, practices can borrow the core ideas: test competence for the intended task, confirm performance clinically and monitor after deployment.
MD Transform's reading
This development is worth following because it affects a real practice decision: workflow fit, data handling, staff capacity, clinical oversight or implementation cost. It should not be interpreted as a product endorsement. The next step is to test the claim against the practice's own workflow, contracts and success measures.